Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 90.52 USD 3.66% Market Closed
Market Cap: 6.3B USD
Have any thoughts about
Lantheus Holdings Inc?
Write Note

Lantheus Holdings Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lantheus Holdings Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Lantheus Holdings Inc
NASDAQ:LNTH
Total Other Income
$74.6m
CAGR 3-Years
N/A
CAGR 5-Years
108%
CAGR 10-Years
62%
Haemonetics Corp
NYSE:HAE
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Total Other Income
$23m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
7%
ICU Medical Inc
NASDAQ:ICUI
Total Other Income
-$322k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Total Other Income
-$10.6m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Total Other Income
$365k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lantheus Holdings Inc
Glance View

Market Cap
6.3B USD
Industry
Health Care

Lantheus Holdings Inc. is a dynamic healthcare company specializing in the development, manufacture, and commercialization of innovative diagnostic imaging agents, particularly in the field of nuclear medicine. Founded in 1956, the company has established a solid reputation for improving patient care through advanced diagnostics, helping healthcare providers make more informed decisions. Lantheus is perhaps best known for its flagship products, including nuclear imaging agents like Pylarify, used in the detection of prostate cancer. With a robust pipeline of novel radiopharmaceuticals in various stages of development, the company is strategically positioned to address unmet needs in diagnostics and therapeutics, thereby enhancing both patient outcomes and shareholder value. For investors, Lantheus represents a compelling opportunity, particularly as the demand for precision medicine continues to grow. With healthcare trends increasingly leaning towards personalized treatment, Lantheus is poised to grow through strategic partnerships, expanding market access, and leveraging new technologies. The company's commitment to innovation is underscored by its recent achievements and promising clinical trials, which have the potential to reshape the landscape of cancer diagnostics and treatment. As Lantheus Holdings continues to expand its portfolio and strengthen its market presence, investors can look forward to both solid financial performance and meaningful contributions to the evolving field of medical diagnostics.

LNTH Intrinsic Value
147.73 USD
Undervaluation 39%
Intrinsic Value
Price

See Also

What is Lantheus Holdings Inc's Total Other Income?
Total Other Income
74.6m USD

Based on the financial report for Sep 30, 2024, Lantheus Holdings Inc's Total Other Income amounts to 74.6m USD.

What is Lantheus Holdings Inc's Total Other Income growth rate?
Total Other Income CAGR 10Y
62%

Back to Top